New antidepressant offers substantial savings

Patients in need of, or currently receiving, selective serotonin reuptake inhibitor (SSRI) therapy now have a branded formulation of paroxetine that is bioequivalent to paroxetine hydrochloride (Paxil, GlaxoSmithKline), yet available at a significant discount. The FDA recently approved paroxetine (Pexeva, Synthon Pharmaceuticals) mesylate for the treatment of major depressive disorder, obsessive/compulsive disorder (OCD), and panic disorder. The product is currently available in pharmacies.